Published in Pharma Business Week, February 20th, 2012
Mr. Leschly is expected to discuss the company's vision for developing gene therapies for genetic diseases with high unmet medical needs, including beta-thalassemia, sickle cell disease and childhood cerebral adrenoleukodystrophy (CCALD). The presentation will include updates on the launch of the company's pivotal CCALD...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week